"Hydrazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substituted derivatives of hydrazine (formula H2N-NH2).
| Descriptor ID |
D006834
|
| MeSH Number(s) |
D02.442
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hydrazines".
Below are MeSH descriptors whose meaning is more specific than "Hydrazines".
This graph shows the total number of publications written about "Hydrazines" by people in this website by year, and whether "Hydrazines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2005 | 1 | 1 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 2 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 1 | 3 |
| 2012 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 2 | 2 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 2 | 0 | 2 |
| 2025 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hydrazines" by people in Profiles.
-
Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment: The PINES Randomized Clinical Trial. JAMA. 2025 11 25; 334(20):1816-1826.
-
Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: phase 2 ESCALATE trial. Blood Adv. 2025 Aug 12; 9(15):3728-3738.
-
Phase I Trial of Selinexor in Pediatric Recurrent/Refractory Solid and CNS Tumors (ADVL1414): A Children's Oncology Group Phase I Consortium Trial. Clin Cancer Res. 2025 May 01; 31(9):1587-1595.
-
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study. Invest New Drugs. 2022 02; 40(1):124-133.
-
Interference of eltrombopag with bilirubin measurements on the Vitros 5600 analyzer. J Clin Lab Anal. 2021 Aug; 35(8):e23796.
-
XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. J Hematol Oncol. 2020 11 04; 13(1):148.
-
Commonly used FRET fluorophores promote collapse of an otherwise disordered protein. Proc Natl Acad Sci U S A. 2019 04 30; 116(18):8889-8894.
-
Veratric acid derivatives containing benzylidene-hydrazine moieties as promising tyrosinase inhibitors and free radical scavengers. Bioorg Med Chem. 2019 06 15; 27(12):2644-2651.
-
Mutant NPM1 Maintains the Leukemic State through HOX Expression. Cancer Cell. 2018 09 10; 34(3):499-512.e9.
-
Loss of p53 expression in cancer cells alters cell cycle response after inhibition of exportin-1 but does not prevent cell death. Cell Cycle. 2018; 17(11):1329-1344.